anonymous
Guest
anonymous
Guest
Daiichi-Sankyo folks, just ignore these negative posters. And don’t comment on what else is coming. Let these chuckleheads find out. Enhertu will be a special, transformational drug.
1) go look up BC rates and mets patients treated third line, that’s our opportunity. 2) assume some share of those patients we’d get, say it’s 25%, 3) multiply those two by our price and that’s our revenue. Not complicated at all and not made up. Just looked up Fierce Bjotech article, they forecast 68M in 2020. The safety concerns are real, talk to Oncs, if they’ll see you and review ad com notes. So you can belive all these I dependent facts from third parties with no cross to bear. Of Keith’s constant posts.